Since the serendipitous discovery 20 years ago of bona fide camelid heavy-chain
antibodies, their single-domain antigen-binding fragments, known as VHHs or nanobodies …

Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by
the many advances in immunology, synthetic biology, and antibody research, different …

By the emergence of recombinant DNA technology, many antibody fragments have been
developed devoid of undesired properties of natural immunoglobulins. Among them …

Antibodies and related proteins comprise one of the largest and fastest-growing classes of
protein pharmaceuticals. A majority of such molecules are monoclonal antibodies; however …

The carbohydrate antigens Tn and sialyl-Tn (STn) are expressed in most carcinomas and
usually absent in healthy tissues. These antigens have been correlated with cancer …

Cancer is one of the most important causes of death all over the world, which has not yet
been treated efficiently. Although several therapeutic approaches have been used, some …

Current guidelines for hypercholesterolemia treatment emphasize lifestyle modification and
lipid‐modifying therapy to reduce the risk for cardiovascular disease. Statins are the primary …

Background The utilization of monoclonal antibodies (moAbs), an issue correlated with the
biopharmaceutical professions, is developing and maturing. Coordinated with this …

At present, single-chain variable fragments (scFv) of antibodies are considered one of the
most important tools in human therapies. Wide applications of antibodies are being …

Antibodies are currently the fastest growing class of therapeutic proteins. When antibody
fragments are included, there are over thirty-five antibody-based medicines approved for …